Role of B Cells in Multiple Sclerosis and Related Disorders

The success of clinical trials of selective B‐cell depletion in patients with relapsing multiple sclerosis (MS) and primary progressive MS has led to a conceptual shift in the understanding of MS pathogenesis, away from the classical model in which T cells were the sole central actors and toward a more complex paradigm with B cells having an essential role in both the inflammatory and neurodegenerative components of the disease process. The role of B cells in MS was selected as the topic of the 27th Annual Meeting of the European Charcot Foundation. Results of the meeting are presented in this concise review, which recaps current concepts underlying the biology and therapeutic rationale behind B‐cell–directed therapeutics in MS, and proposes strategies to optimize the use of existing anti–B‐cell treatments and provide future directions for research in this area. ANN NEUROL 2021;89:13–23

• Publication year

  2020

• Venue

  Annals of Neurology

• Publication date

  2020-10-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ana.25927PMID 33091175PMCID PMC8007167
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody

  2020cited by this paper
• Impact of treatment on cellular immunophenotype in MS

  2020cited by this paper
• Intrathecal immunoglobulins and neurofilament light after autologous haematopoietic stem cell transplantation for multiple sclerosis

  2020cited by this paper
• A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis

  2020cited by this paper
• Progress in Multiple Sclerosis Research: An Example of Bedside to Bench.

  2020cited by this paper
• Ofatumumab versus Teriflunomide in Multiple Sclerosis.

  2020cited by this paper
• Characterization of leptomeningeal inflammation in rodent experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis

  2019cited by this paper
• Anti-CD20 therapy depletes activated myelin-specific CD8+ T cells in multiple sclerosis

  2019cited by this paper
• Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers

  2019cited by this paper
• Iron homeostasis, complement, and coagulation cascade as CSF signature of cortical lesions in early multiple sclerosis

  2019cited by this paper
• Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

  2019cited by this paper
• Comparison of Clinical Outcomes of Transverse Myelitis Among Adults With Myelin Oligodendrocyte Glycoprotein Antibody vs Aquaporin-4 Antibody Disease

  2019cited by this paper
• Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis.

  2019cited by this paper
• Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis

  2019cited by this paper
• Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis

  2019cited by this paper
• CD4+ count‐dependent concentration–effect relationship of rituximab in rheumatoid arthritis

  2019cited by this paper
• Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.

  2019cited by this paper
• Membrane assembly of aquaporin-4 autoantibodies regulates classical complement activation in neuromyelitis optica.

  2019cited by this paper
• Neuromyelitis optica spectrum disorders: still evolving and broadening

  2019cited by this paper
• Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.

  2019cited by this paper
• Myelin oligodendrocyte glycoprotein antibodies in neurological disease

  2018cited by this paper
• Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat

  2018cited by this paper
• Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations

  2018cited by this paper
• Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease

  2018cited by this paper
• Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis

  2018cited by this paper
• Reassessing B cell contributions in multiple sclerosis

  2018cited by this paper
• Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein

  2018cited by this paper
• Restoration of regulatory B cell deficiency following alemtuzumab therapy in patients with relapsing multiple sclerosis

  2018cited by this paper
• The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells

  2018cited by this paper
• Intrathecal treatment trial of rituximab in progressive MS

  2018cited by this paper
• ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

  2018cited by this paper
• Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

  2018cited by this paper
• Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients

  2018cited by this paper
• Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis

  2018cited by this paper
• Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells

  2018cited by this paper
• No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

  2018cited by this paper
• Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis

  2018cited by this paper
• Inflammatory intrathecal profiles and cortical damage in multiple sclerosis

  2018cited by this paper
• CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications

  2018cited by this paper
• Imaging of meningeal inflammation should become part of the routine MRI protocol – Yes

  2018cited by this paper
• Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial

  2018cited by this paper
• Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study

  2017cited by this paper
• Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

  2017cited by this paper
• Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination

  2017cited by this paper
• Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma

  2017cited by this paper
• Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor

  2017cited by this paper
• Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination

  2017cited by this paper
• Pediatric versus adult MS: similar or different?

  2017cited by this paper
• Clinical presentation and prognosis in MOG-antibody disease: a UK study

  2017cited by this paper
• Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study.

  2017cited by this paper
• B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro.

  2017cited by this paper
• Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis

  2017cited by this paper
• Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

  2017cited by this paper
• Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

  2016cited by this paper
• Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins

  2016cited by this paper
• Rituximab in paediatric onset multiple sclerosis: a case series

  2016influential reference
• The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets.

  2016cited by this paper
• The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research.

  2016influential reference
• Rituximab in multiple sclerosis

  2016cited by this paper
• Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

  2015cited by this paper
• Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy

  2015cited by this paper
• Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation.

  2015cited by this paper
• MOG cell-based assay detects non-MS patients with inflammatory neurologic disease

  2015cited by this paper
• Defining the clinical course of multiple sclerosis: The 2013 revisions

  2015cited by this paper
• International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

  2015cited by this paper
• Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis

  2015cited by this paper
• B cells populating the multiple sclerosis brain mature in the draining cervical lymph nodes

  2014cited by this paper
• Rituximab use in pediatric central demyelinating disease.

  2014influential reference
• Defining the clinical course of multiple sclerosis

  2014cited by this paper
• Targets of the humoral autoimmune response in multiple sclerosis.

  2014influential reference
• Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.

  2014cited by this paper
• Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis

  2014cited by this paper
• Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica

  2013cited by this paper
• Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica

  2013cited by this paper
• Disease-modifying treatments for progressive multiple sclerosis

  2013cited by this paper
• B cell exchange across the blood-brain barrier in multiple sclerosis.

  2012cited by this paper
• Rituximab Therapy Leads to Reduced Imprints of Receptor Revision in Immunoglobulin κ and λ Light Chains

  2012cited by this paper
• Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro.

  2012cited by this paper
• Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

  2011cited by this paper
• Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.

  2011cited by this paper
• Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

  2011cited by this paper
• Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?

  2010cited by this paper
• Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial

  2009cited by this paper
• A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis

  2009cited by this paper
• Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis

  2008influential reference
• B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

  2008cited by this paper
• Helminth infections associated with multiple sclerosis induce regulatory B cells

  2008cited by this paper
• Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain

  2008cited by this paper
• Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial

  2007cited by this paper
• Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.

  2007cited by this paper
• Lack of association between antimyelin antibodies and progression to multiple sclerosis.

  2007cited by this paper
• Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain

  2007cited by this paper
• Lymphoid neogenesis in chronic inflammatory diseases

  2006cited by this paper
• B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation

  2006cited by this paper
• Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.

  2006cited by this paper
• Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.

  2006cited by this paper
• Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.

  2006cited by this paper
• BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

  2005cited by this paper
• Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis

  2003cited by this paper
• Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.

  2003influential reference

• Two-year OCT follow-up in multiple sclerosis patients on Ofatumumab shows retinal preservation over non-antiCD20 treatments

  2026cites this paper
• Organism-wide cellular dynamics and epigenomic remodeling in mammalian aging.

  2026cites this paper
• The efficacy and safety of divozilimab in real-world clinical practice

  2026cites this paper
• Macrophage-targeted PEGylated liposomes ameliorate experimental autoimmune encephalomyelitis

  2026cites this paper
• Dual-Targeting miR-219 and miR-146a in Multiple Sclerosis: Bridging Myelin Repair and Neuroinflammation for Novel Therapeutic Insights

  2026cites this paper
• Engineering neuroimmune regulation: biomaterial and nanotechnology platforms for neuropathology diagnosis and targeted immunomodulation

  2026cites this paper
• CAR T-Cell Immunotherapy in Neuroautoimmune Diseases: Focus on the Central Nervous System.

  2026cites this paper
• Pathogenesis of Multiple Sclerosis with Special Consideration of Iron Metabolism, Ferroptosis and Other Forms of Programmed Cell Death.

  2026cites this paper
• Myelin antigen capture in the CNS by B cells expressing EBV latent membrane protein 1 leads to demyelinating lesion formation.

  2026cites this paper
• Innate lymphoid cells: unsung heroes or villains in multiple sclerosis pathogenesis?

  2026cites this paper
• Analysis of common differential gene expression between rheumatoid arthritis and ulcerative colitis

  2026cites this paper
• Epigenetic dysregulation of B-cells in autoimmune diseases and lymphomas (Review)

  2026cites this paper
• Organism-wide cellular dynamics and epigenomic remodeling in mammalian aging

  2025cites this paper
• Updates on immunosuppressant safety and malignancy risk in patients with multiple sclerosis

  2025cites this paper
• Gynecological health: A missing link in comprehensive treatment monitoring for multiple sclerosis

  2025cites this paper
• The frequency of psoriasis in Australian multiple sclerosis patients

  2025cites this paper
• White Matter in Crisis: Oligodendrocytes and the Pathophysiology of Multiple Sclerosis

  2025cites this paper
• Therapeutic Plasma Exchange in Corticosteroid-Refractory Multiple Sclerosis Relapses: Mechanisms, Efficacy, and Integration into Clinical Practice

  2025cites this paper
• B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumab

  2025cites this paper
• Targeting Lifestyle in CNS Inflammatory Demyelinating Diseases: Insights from Diet and Exercise as Potential Disease Modifiers

  2025cites this paper
• Immunosenescence: Molecular Mechanisms, Diseases, and Therapeutic Innovations

  2025cites this paper
• Effectiveness of Rituximab in rElapsiNg Multiple SclErosis previously treated with hiGhly-Active Disease modifying thErapies (RENEGADE study)

  2025cites this paper
• FCRL5, a B-Cell Marker With Novel Diagnostic and Prognostic Value for Multiple Sclerosis

  2025cites this paper
• Immunological Monitoring During Anti-CD20 Therapies to Predict Infection Risk and Treatment Response in Multiple Sclerosis Patients

  2025cites this paper
• IgT and IgD dominance in the teleost central nervous system

  2025cites this paper
• White Blood Cells in Neurodegenerative Diseases in the Context of Neuroinflammation

  2025cites this paper
• [Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis].

  2025cites this paper
• Translational medicine research on the role of key gene network modulation mediated by procyanidin B2 in the precise diagnosis and treatment of multiple sclerosis

  2025influential citation
• NEK2 regulates B cell function and the severity of experimental autoimmune encephalomyelitis

  2025cites this paper
• Overtime Challenges of Diagnosis and Treatment in Two Pediatric Patients with Extensive Cerebral Tumefactive Lesions Indicative of Baló’s Type Multiple Sclerosis

  2025cites this paper
• Dynamic Regulation of Macrophage Polarization in Acute Myocardial Infarction and Its Therapeutic Potential

  2025cites this paper
• Single-cell RNA sequencing of cerebrospinal fluid immune cells in relapsing–remitting multiple sclerosis: insights into cellular composition and immune dynamics

  2025cites this paper
• Chronic Cavitary Pulmonary Histoplasmosis–Novel Concepts Regarding Pathogenesis

  2025cites this paper
• T-B cell cooperation in ectopic lymphoid follicles propagates CNS autoimmunity.

  2025cites this paper
• Multiple sclerosis pathophysiology: a comprehensive review of genetic, environmental, and immunological drivers

  2025cites this paper
• JC polyomavirus neuroinvasion across the blood-brain barrier: Current understanding and emerging perspectives

  2025cites this paper
• New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies

  2025cites this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide as serum biomarkers in a sample of Egyptian multiple sclerosis patients

  2025cites this paper
• Bruton’s Tyrosine Kinase: A Potential Novel Target for Neurological Disorders

  2025cites this paper
• The CXCL13-CXCR5 axis and follicular cytotoxic T cells: Linking T-B crosstalk in autoimmune diseases.

  2025cites this paper
• Utility of transorbital ultrasound to assess disability and axonal loss in multiple sclerosis

  2025cites this paper
• Reduced CD40 expression in B cell subsets of individuals with radiologically isolated syndrome

  2025cites this paper
• Neuromodulatory role and therapeutic potential of N6-methyladenosine RNA methylation in neurodegenerative diseases.

  2025cites this paper
• Biosafety assessment of engineered CCL20 locked dimers in vivo

  2025cites this paper
• Shaping the role of plasma exchange in autoimmune neurology: lessons learned from 67 years and over 90,000 procedures

  2025cites this paper
• CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders

  2025cites this paper
• CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective

  2025cites this paper
• Intrathecal Immunoglobulin A Synthesis in Multiple Sclerosis: From Biological Aspects to Clinical Relevance

  2025cites this paper
• Exploring the Pathophysiology, Diagnosis, and Treatment Options of Multiple Sclerosis.

  2025cites this paper
• Persistent Classical and Atypical Memory B Cells Underlie Heterogeneous Vaccine Responses in Ocrelizumab-Treated Multiple Sclerosis

  2025cites this paper
• Impact of kynurenine metabolites on B and T cells in multiple sclerosis and allergies

  2025cites this paper
• Role of innate immune cells in multiple sclerosis

  2025cites this paper
• Transcriptomic analysis of the physiological responses to injuries induced accompanying intracortical microelectrode implantation.

  2025cites this paper
• Neuroinflammatory canine disorders: unveiling disease mechanisms from a One Health perspective.

  2025cites this paper
• High-Fat Diet—Shared Environmental Risk Factor for Amyotrophic Lateral Sclerosis and Multiple Sclerosis

  2025cites this paper
• Multiple Sklerose und Onkologie: Neue Perspektiven an der Schnittstelle zweier Disziplinen

  2025cites this paper
• Kappa Free Light Chain Index Correlates With Prognostic Biomarkers in Multiple Sclerosis and Decreases Slowly Following Treatment

  2025cites this paper
• Cladribine tablets in the new multiple sclerosis era

  2025cites this paper
• The Elusive B Cell Antigen in Multiple Sclerosis: Time to Rethink CNS B Cell Functions

  2025cites this paper
• Therapeutic B cell depletion identifies immunoregulatory networks

  2025cites this paper
• Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis

  2025cites this paper
• Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms

  2025cites this paper
• Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subtypes in multiple sclerosis patients without impacting durable COVID-19 vaccine responses

  2025cites this paper
• Role of dietary fiber and short-chain fatty acids in preventing neurodegenerative diseases through the gut-brain axis

  2025cites this paper
• Germinal center trajectories and transcriptional signatures define CLL subtypes and their pathway regulators

  2025cites this paper
• Silent Synapses in Multiple Sclerosis: From Synaptic Dysfunction to Reactivation‐Based Therapies—A Narrative Review of Cognitive and Neuroplasticity Outcomes

  2025cites this paper
• Efficacy and Immunological Impact of Intrathecal Baclofen Pumps in Managing Spasticity in Multiple Sclerosis in Adult Patients: A Systematic Review

  2025cites this paper
• A Window into New Insights on Progression Independent of Relapse Activity in Multiple Sclerosis: Role of Therapies and Current Perspective

  2025cites this paper
• Revitalizando las terapias en enfermedades autoinmunes: Nanopartículas como alternativa de tratamiento

  2025cites this paper
• A New Perspective on Mechanisms of Neurodegeneration in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: the Early and Critical Role of Platelets in Neuro/Axonal Loss

  2025cites this paper
• Secreted IgM deficiency alters the retinal landscape enhancing neurodegeneration associated with aging

  2025cites this paper
• Neuroinflammation: An Oligodendrocentric View

  2025cites this paper
• Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L)

  2025cites this paper
• Patterns of autoantibody expression in multiple sclerosis identified through development of an autoantigen discovery technology

  2025cites this paper
• Transcriptomic profiling after B cell depletion reveals central and peripheral immune cell changes in multiple sclerosis

  2025cites this paper
• Rituximab for people with multiple sclerosis.

  2025cites this paper
• Revisiting Migraine Pathophysiology: from Neurons To Immune Cells Through Lens of Immune Regulatory Pathways

  2025cites this paper
• Update on novel multiple sclerosis treatments: from dismal defeat to scintillating success

  2025cites this paper
• Epstein-Barr virus, vitamin D and the immune response: connections with consequences for multiple sclerosis

  2024cites this paper
• CHI3L1 in Multiple Sclerosis—From Bench to Clinic

  2024cites this paper
• Interaction between Th17 and central nervous system in multiple sclerosis

  2024cites this paper
• Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy

  2024cites this paper
• Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy.

  2024cites this paper
• Ofatumumab for multiple sclerosis with disability accumulation.

  2024cites this paper
• The Polygenic Nature of Multiple Sclerosis: Genetic Variants, Immunological Modulation, and Environmental Connections

  2024cites this paper
• Epstein-Barr virus infection in patients with MOGAD

  2024cites this paper
• Human B-cells can form hetero-aggregates with blood platelets: a novel insight into adaptive immunity regulation in multiple sclerosis.

  2024cites this paper
• Sportizumab - Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial.

  2024cites this paper
• Dawn of CAR-T cell therapy in autoimmune diseases

  2024cites this paper
• T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination

  2024cites this paper
• Comparative analysis of the B cell receptor repertoire during relapse and remission in patients with multiple sclerosis.

  2024cites this paper
• Selected Aspects of the Neuroimmunology of Cell Therapies for Neurologic Disease

  2024cites this paper
• Modern Russian drugs for the treatment of neurodegenerative diseases

  2024cites this paper
• Tertiary lymphoid structures and B-cell infiltration are IPF features with functional consequences

  2024cites this paper
• Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways

  2024cites this paper
• Coeliac disease as a model for understanding multiple sclerosis

  2024cites this paper
• Frequency-potency analysis of IgG+ memory B cells delineates neutralizing antibody responses at single-cell resolution

  2024cites this paper
• A review of intravenous immunoglobulin in the treatment of neuroimmune conditions, acute COVID-19 infection, and post-acute sequelae of COVID-19 Syndrome.

  2024cites this paper
• BTK and YKL-40 Levels and Their Association with Acute AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder

  2024cites this paper
• Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis

  2024cites this paper